Biocartis Adds $100M Equity Financing
Swiss biotech start-up Biocartis has raised 71 million euro ($100 million) in Series C financing. Investors in the round include Debiopharm Group, Philips, Johnson & Johnson Development Corp., the Wellcome Trust, Korys, Valiance and Biovest. The money will be used to help commercialize the company’s compact molecular diagnostics system.
17 November 2011•5 mins read
